Source of cannabinoids: what is available, what is used, and where does it come from?

Author:

Specchio Nicola1,Pietrafusa Nicola1,Cross Helen J.2

Affiliation:

1. Rare and Complex Epilepsy Unit, Department of Neurosciences Bambino Gesù Children's Hospital, IRCCS, Member of the European Reference Network EpiCARE Rome Italy

2. UCL‐Institute of Child Health Great Ormond Street Hospital for Children, Member of the European Reference Network EpiCARE, London & Young Epilepsy Lingfield UK

Abstract

ABSTRACT Cannabis sativa L . is an ancient medicinal plant wherefrom over 120 cannabinoids are extracted. In the past two decades, there has been increasing interest in the therapeutic potential of cannabis‐based treatments for neurological disorders such as epilepsy, and there is now evidence for the medical use of cannabis and its effectiveness for a wide range of diseases. Cannabinoid treatments for pain and spasticity in patients with multiple sclerosis (Nabiximols) have been approved in several countries. Cannabidiol (CBD), in contrast to tetra‐hydro‐cannabidiol (THC), is not a controlled substance in the European Union, and over the years there has been increasing use of CBD‐enriched extracts and pure CBD for seizure disorders, particularly in children. No analytical controls are mandatory for CBD‐based products and a pronounced variability in CBD concentrations in commercialized CBD oil preparations has been identified. Randomized controlled trials of plant‐derived CBD for treatment of Lennox‐Gastaut syndrome (LGS) and Dravet syndrome (DS) have provided evidence of anti‐seizure effects, and in June 2018, CBD was approved by the Food and Drug Administration as an add‐on antiepileptic drug for patients two years of age and older with LGS or DS. Medical cannabis, with various ratios of CBD and THC and in different galenic preparations, is licensed in many European countries for several indications, and in July 2019, the European Medicines Agency also granted marketing authorisation for CBD in association with clobazam, for the treatment of seizures associated with LGS or DS. The purpose of this article is to review the availability of cannabis‐based products and cannabinoid‐based medicines, together with current regulations regarding indications in Europe (as of July 2019). The lack of approval by the central agencies, as well as social and political influences, have led to significant variation in usage between countries.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3